Revvity Inc (RVTY)

$98.89 +1.32 (1.35%)
Market Cap 11.33B
Revenue (ttm) 2.76B
Net Income (ttm) 270.39M
EPS (ttm) N/A
PE Ratio 19.57
Forward PE 19.66
Profit Margin 9.81%
Debt to Equity Ratio 0.43
Volume 2,102,100
Avg Vol 1,232,384
Day's Range N/A - N/A
Shares Out 116.07M
Stochastic %K 87%
Beta 0.98
Analysts Strong Sell
Price Target $112.00

Company Profile

Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and sc...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 781 663 6900
Address:
77 4th Avenue, Waltham, United States
AldoAlex2000
AldoAlex2000 Oct. 24 at 7:04 PM
$RVTY Hi! @Olddrache when you have a chance could you share the rvty flow with me, please?
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 24 at 3:54 PM
🏛️ 🚀 $RVTY up ⬆️19.73% since our entry $83.83 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
OptionRunners
OptionRunners Oct. 24 at 3:32 PM
$RVTY Buyer of the November 21st $105/$90 bull risk reversals 1,500 times for $1.00 ahead of earnings on Monday pre market
0 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 11:01 AM
$RVTY Q3 earnings — strength or struggle ahead? Life Sciences looks solid with rising demand fueling segmental growth, but the Diagnostic segment could drag due to headwinds in China. Full breakdown of what to watch in RVTY’s Q3 report 👉 https://www.zacks.com/stock/news/2774901/will-rvty-q3-earnings-reflect-segmental-strength-amid-rising-demand?cid=sm-stocktwits-2-2774901-teaser-17209&ADID=SYND_STOCKTWITS_TWEET_2_2774901_TEASER_17209
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 22 at 2:19 PM
$RVTY Share Price: $97.02 Contract Selected: Jun 18, 2026 $120 Calls Buy Zone: $3.06 – $3.78 Target Zone: $4.98 – $6.08 Potential Upside: 54% ROI Time to Expiration: 238 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 20 at 10:12 PM
🏛️ 🚀 $RVTY up ⬆️15.79% since our entry $83.83 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 12:54 PM
Enter: $RVTY NOV 21 2025 $95 CALLS Buy in Price: $5.40 - $6.30 Take Profit: $9.07 Stop Bleeding: $4.75 ROI Potential: 68% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 16 at 5:23 PM
$RVTY Share Price: $95.10 Contract Selected: Mar 20, 2026 $95 Calls Buy Zone: $7.31 – $9.03 Target Zone: $12.19 – $14.90 Potential Upside: 58% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Oct. 16 at 2:23 PM
$RVTY China is a big portion of their business … Beware ….
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 12:52 PM
Guggenheim updates rating for Revvity ( $RVTY ) to Neutral.
0 · Reply
Latest News on RVTY
Revvity Board Declares Quarterly Dividend

Oct 23, 2025, 4:05 PM EDT - 1 day ago

Revvity Board Declares Quarterly Dividend

Revvity Showcases Progress with Purpose in 2025 Impact Report

Oct 14, 2025, 8:00 AM EDT - 11 days ago

Revvity Showcases Progress with Purpose in 2025 Impact Report

Revvity to Hold Earnings Call on Monday, October 27, 2025

Oct 6, 2025, 8:00 AM EDT - 19 days ago

Revvity to Hold Earnings Call on Monday, October 27, 2025

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

Oct 2, 2025, 8:00 AM EDT - 23 days ago

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

SNY

Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

Sep 29, 2025, 8:00 AM EDT - 26 days ago

Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems

Sep 22, 2025, 8:00 AM EDT - 4 weeks ago

Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems

Revvity, Inc. (RVTY) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Sep 9, 2025, 5:31 PM EDT - 6 weeks ago

Revvity, Inc. (RVTY) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Revvity, Inc. (RVTY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 3, 2025, 10:40 AM EDT - 7 weeks ago

Revvity, Inc. (RVTY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

Sep 2, 2025, 8:00 AM EDT - 7 weeks ago

Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

Revvity to Present at Upcoming Investor Conferences

Aug 18, 2025, 8:00 AM EDT - 2 months ago

Revvity to Present at Upcoming Investor Conferences

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

Aug 6, 2025, 8:00 AM EDT - 2 months ago

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

Revvity Q2: Headwinds From China And Customers, Buy On Weakness

Jul 28, 2025, 2:47 PM EDT - 3 months ago

Revvity Q2: Headwinds From China And Customers, Buy On Weakness

Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook

Jul 28, 2025, 1:40 PM EDT - 3 months ago

Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook

Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More

Jul 28, 2025, 12:25 PM EDT - 3 months ago

Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More

LNG NKE

Revvity, Inc. (RVTY) Q2 2025 Earnings Call Transcript

Jul 28, 2025, 11:59 AM EDT - 3 months ago

Revvity, Inc. (RVTY) Q2 2025 Earnings Call Transcript

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Jul 28, 2025, 8:13 AM EDT - 3 months ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ATAI

Revvity trims 2025 profit forecast on soft demand for diagnostics in China

Jul 28, 2025, 8:09 AM EDT - 3 months ago

Revvity trims 2025 profit forecast on soft demand for diagnostics in China

Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.

Jul 28, 2025, 7:39 AM EDT - 3 months ago

Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.

Revvity Announces Financial Results for the Second Quarter of 2025

Jul 28, 2025, 6:00 AM EDT - 3 months ago

Revvity Announces Financial Results for the Second Quarter of 2025

Revvity to Hold Earnings Call on Monday, July 28, 2025

Jul 7, 2025, 8:00 AM EDT - 3 months ago

Revvity to Hold Earnings Call on Monday, July 28, 2025

Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows

Jun 2, 2025, 8:00 AM EDT - 5 months ago

Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

May 19, 2025, 8:00 AM EDT - 5 months ago

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy

May 9, 2025, 10:35 AM EDT - 6 months ago

Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy

Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 11:49 AM EDT - 6 months ago

Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop

Apr 28, 2025, 9:14 AM EDT - 6 months ago

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop

Revvity beats quarterly estimates on steady demand for medical equipment

Apr 28, 2025, 7:32 AM EDT - 6 months ago

Revvity beats quarterly estimates on steady demand for medical equipment

Revvity Announces Financial Results for the First Quarter of 2025

Apr 28, 2025, 6:00 AM EDT - 6 months ago

Revvity Announces Financial Results for the First Quarter of 2025

Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation

Apr 23, 2025, 8:00 AM EDT - 6 months ago

Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation

Revvity Fuels the Future of Cancer Science with New Research Solutions

Apr 22, 2025, 8:00 AM EDT - 6 months ago

Revvity Fuels the Future of Cancer Science with New Research Solutions

RSSS

Revvity to Hold Earnings Call on Monday, April 28, 2025

Apr 3, 2025, 8:00 AM EDT - 7 months ago

Revvity to Hold Earnings Call on Monday, April 28, 2025

Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery

Apr 2, 2025, 8:00 AM EDT - 7 months ago

Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

Apr 2, 2025, 8:00 AM EDT - 7 months ago

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

Mar 20, 2025, 1:00 PM EDT - 7 months ago

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

PerkinElmer Acquires Project Farma, Expanding Its OneSource Professional Services Offering for the Life Sciences Industry

Mar 11, 2025, 12:00 PM EDT - 8 months ago

PerkinElmer Acquires Project Farma, Expanding Its OneSource Professional Services Offering for the Life Sciences Industry

Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay

Mar 3, 2025, 8:00 AM EST - 8 months ago

Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay

Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group

Feb 20, 2025, 12:30 PM EST - 8 months ago

Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group

Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript

Jan 31, 2025, 9:34 AM EST - 9 months ago

Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript

Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending

Jan 31, 2025, 7:32 AM EST - 9 months ago

Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024

Jan 31, 2025, 6:00 AM EST - 9 months ago

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024

Revvity Ignites Scientific Breakthroughs at SLAS2025

Jan 23, 2025, 8:00 AM EST - 9 months ago

Revvity Ignites Scientific Breakthroughs at SLAS2025

Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

Jan 13, 2025, 8:00 AM EST - 10 months ago

Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance

Jan 12, 2025, 5:00 PM EST - 10 months ago

Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance

Revvity Announces FDA Clearance for First Automated Free Testosterone Test

Jan 10, 2025, 8:00 AM EST - 10 months ago

Revvity Announces FDA Clearance for First Automated Free Testosterone Test

Revvity to Present at J.P. Morgan Healthcare Conference

Dec 17, 2024, 8:00 AM EST - 11 months ago

Revvity to Present at J.P. Morgan Healthcare Conference

Safe Biopharma: Revvity's Recurring Revenues And Diagnostics

Dec 16, 2024, 12:27 AM EST - 11 months ago

Safe Biopharma: Revvity's Recurring Revenues And Diagnostics

Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst

Dec 13, 2024, 1:57 PM EST - 11 months ago

Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst

DHR

Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK

Nov 20, 2024, 8:00 AM EST - 1 year ago

Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK

Scale Biosciences and Revvity's BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells

Nov 19, 2024, 8:00 AM EST - 1 year ago

Scale Biosciences and Revvity's BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells

Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference

Nov 19, 2024, 8:00 AM EST - 1 year ago

Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference

Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation

Nov 18, 2024, 8:00 AM EST - 1 year ago

Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation

AldoAlex2000
AldoAlex2000 Oct. 24 at 7:04 PM
$RVTY Hi! @Olddrache when you have a chance could you share the rvty flow with me, please?
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 24 at 3:54 PM
🏛️ 🚀 $RVTY up ⬆️19.73% since our entry $83.83 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
OptionRunners
OptionRunners Oct. 24 at 3:32 PM
$RVTY Buyer of the November 21st $105/$90 bull risk reversals 1,500 times for $1.00 ahead of earnings on Monday pre market
0 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 11:01 AM
$RVTY Q3 earnings — strength or struggle ahead? Life Sciences looks solid with rising demand fueling segmental growth, but the Diagnostic segment could drag due to headwinds in China. Full breakdown of what to watch in RVTY’s Q3 report 👉 https://www.zacks.com/stock/news/2774901/will-rvty-q3-earnings-reflect-segmental-strength-amid-rising-demand?cid=sm-stocktwits-2-2774901-teaser-17209&ADID=SYND_STOCKTWITS_TWEET_2_2774901_TEASER_17209
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 22 at 2:19 PM
$RVTY Share Price: $97.02 Contract Selected: Jun 18, 2026 $120 Calls Buy Zone: $3.06 – $3.78 Target Zone: $4.98 – $6.08 Potential Upside: 54% ROI Time to Expiration: 238 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 20 at 10:12 PM
🏛️ 🚀 $RVTY up ⬆️15.79% since our entry $83.83 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 12:54 PM
Enter: $RVTY NOV 21 2025 $95 CALLS Buy in Price: $5.40 - $6.30 Take Profit: $9.07 Stop Bleeding: $4.75 ROI Potential: 68% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 16 at 5:23 PM
$RVTY Share Price: $95.10 Contract Selected: Mar 20, 2026 $95 Calls Buy Zone: $7.31 – $9.03 Target Zone: $12.19 – $14.90 Potential Upside: 58% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Oct. 16 at 2:23 PM
$RVTY China is a big portion of their business … Beware ….
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 12:52 PM
Guggenheim updates rating for Revvity ( $RVTY ) to Neutral.
0 · Reply
ZacksResearch
ZacksResearch Oct. 9 at 4:56 PM
$RVTY teams up with Sanofi — a big move into broader diagnostics 🚀 This partnership launches a scalable test for early Type 1 Diabetes detection, marking a major step beyond RVTY’s rare disease focus. See what this expansion means for the company’s growth potential 👉 https://www.zacks.com/stock/news/2765697/rvty-collaborates-with-sanofi-for-early-detection-of-type-1-diabetes?cid=sm-stocktwits-2-2765697-teaser-15405&ADID=SYND_STOCKTWITS_TWEET_2_2765697_TEASER_15405
0 · Reply
ZacksResearch
ZacksResearch Oct. 9 at 3:56 PM
$RVTY: Can Revvity's new diabetes initiative generate positive investor sentiment? 🤔 The T1D early detection program is supported by Sanofi, aiming to push Revvity beyond rare disease markets and into large-scale clinical testing. This strategic move could position RVTY for long-term growth if key regulatory milestones are reached and commercialization succeeds. Explore the strategic implications. https://www.zacks.com/stock/news/2765697/rvty-collaborates-with-sanofi-for-early-detection-of-type-1-diabetes?cid=sm-stocktwits-2-2765697-body-15407&ADID=SYND_STOCKTWITS_TWEET_2_2765697_BODY_15407
0 · Reply
JarvisFlow
JarvisFlow Oct. 7 at 5:52 PM
Evercore ISI Group has adjusted their stance on Revvity ( $RVTY ), setting the rating to Outperform with a target price of 108 → 106.
0 · Reply
TradeInYourJob
TradeInYourJob Oct. 5 at 1:49 AM
$RVTY no position currently but looks like a good add
0 · Reply
StockAutoPro
StockAutoPro Oct. 4 at 10:31 PM
$RVTY: Buy target $92.05 Sell target $98.75 Bullish trend in digital real estate could boost growth for leading virtual property platforms.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 4 at 12:43 AM
Enter: $RVTY NOV 21 2025 $95 CALLS Buy in Price: $3.93 - $4.10 Take Profit: $5.19 Stop Bleeding: $3.46 ROI Potential: 32% Exit Within: 109 Minutes https://moneygroup.us/alerts
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 2 at 7:23 PM
🏛️ 🚀 $RVTY up ⬆️10.39% since our entry $83.83 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 1 at 5:01 PM
🏛️ 🚀 $RVTY up ⬆️8.46% since our entry $83.83 on Sep 26, 2025 👉 FREE TRIAL! Check bio. ALL signals Time stamped. NO B.S.!
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 30 at 5:33 PM
🎯 Target Hit 🏁 📨 Signal From Sep 26, 2025 🏛️ $RVTY 💵 Entry: $83.8300 ✅ Exit: $86.6215 💰 P/L: +3.33% 👉 Check bio for full access
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 26 at 3:02 PM
🚀 New Signal ✅ 🏛️ $RVTY 🗓️ Sep 26, 2025 💵 Entry: $83.83 🎯 Target (Opt.): $86.62 (+3.33%) 👉 Check bio for full access
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 26 at 2:01 AM
Enter: $RVTY OCT 17 2025 $85 CALLS Buy in Price: $3.90 - $5.00 Take Profit: $6.40 Stop Bleeding: $3.43 ROI Potential: 64% Exit Within: 288 Minutes https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Sep. 22 at 6:07 PM
B of A Securities updates rating for Revvity ( $RVTY ) to Buy, target set at 110 → 99.
0 · Reply